• Your shopping cart is empty!

PDF Preview

CLSI C43-A2

Gas Chromatography/Mass Spectrometry Confirmation of Drugs; Approved Guideline-Second Edition, C43A2E

Clinical and Laboratory Standards Institute, 03/01/2010

Publisher: CLSI

File Format: PDF

$90.00$180.00


Published:01/03/2010

File Size:1 file , 2 MB

Note:This product is unavailable in Russia, Belarus

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of September 2016. Because of its value to the laboratory community, it is being retained in CLSI's library.

This document provides guidance on establishing uniform practices necessary to produce quality data for quantitation and identification of a drug or drug metabolite using the gas chromatography/mass spectrometry method. Specific quality assurance criteria for maintaining and documenting optimal instrument performance are also presented.

More CLSI standard pdf

CLSI NBS02-A2

CLSI NBS02-A2

Newborn Screening Follow-up; Approved Guideline - Second Edition, NSB02A2

$90.00 $180.00

CLSI MM14-A2 (R2018)

CLSI MM14-A2 (R2018)

Design of Molecular Proficiency Testing/External Quality Assessment; Approved Guideline - Second Edition, MM14A2E

$90.00 $180.00

CLSI VET01-A4 and VET01-S2

CLSI VET01-A4 and VET01-S2

Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial Isolated from Animals; Approved Standard-Fourth Edition and Supplement, VET01A4E and VET01S2E

$144.00 $289.01

CLSI NBS06-A

CLSI NBS06-A

Newborn Blood Spot Screening for Severe Combined Immunodeficiency by Measurement of T-cell Receptor Excision Circles; Approved Guideline, NBS06AE

$90.00 $180.00